四川汇宇制药股份有限公司自愿披露HYP-6589片联合用药获得药物临床试验批准通知书的公告

Group 1: Drug Development Announcement - Sichuan Huiyu Pharmaceutical Co., Ltd. announced that its subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of the innovative drug HYP-6589 tablets in combination with Osimertinib for treating advanced non-small cell lung cancer with target-driven gene positivity [1][2] - HYP-6589 is classified as a Class 1 innovative chemical drug and is intended for use in clinical trials within China [1][2] - The drug targets the SOS1 protein, which plays a crucial role in the RAS signaling pathway, and preclinical studies indicate that combining SOS1 inhibitors with Osimertinib can enhance therapeutic efficacy and potentially overcome resistance mechanisms [3] Group 2: Market Context and Competitive Landscape - As of the announcement date, there are no similar products approved for market release domestically or internationally, indicating a unique market opportunity for HYP-6589 [4] Group 3: Shareholder Reduction Plan - Major shareholder Huang Qianyi holds 27,219,439 shares, representing 6.426% of the total share capital, which are subject to judicial freeze [6][7] - Huang Qianyi plans to reduce his holdings by 1,300,000 shares due to a court ruling, with the reduction expected to begin on February 3, 2026, through a centralized bidding process [7][8] - The reduction is mandated by a court order and is not expected to impact the company's governance structure or ongoing operations [8][9]